These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 22910440)

  • 81. FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer.
    Cohen MH; Gootenberg J; Keegan P; Pazdur R
    Oncologist; 2007 Jun; 12(6):713-8. PubMed ID: 17602060
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Treatment rationale and study design for a randomized trial of pemetrexed/carboplatin followed by maintenance pemetrexed versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with advanced non-small-cell lung cancer of nonsquamous histology.
    Zinner RG; Saxman SB; Peng G; Monberg MJ; Ortuzar WI
    Clin Lung Cancer; 2010 Sep; 11(5):352-7. PubMed ID: 20837462
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Simulations using a drug-disease modeling framework and phase II data predict phase III survival outcome in first-line non-small-cell lung cancer.
    Claret L; Lu JF; Bruno R; Hsu CP; Hei YJ; Sun YN
    Clin Pharmacol Ther; 2012 Nov; 92(5):631-4. PubMed ID: 22910440
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Efficacy of motesanib diphosphate in non-small-cell lung cancer.
    Rijavec E; Genova C; Barletta G; Biello F; Dal Bello MG; Coco S; Truini A; Vanni I; Alama A; Boccardo F; Grossi F
    Expert Opin Pharmacother; 2014 Aug; 15(12):1771-80. PubMed ID: 25032887
    [TBL] [Abstract][Full Text] [Related]  

  • 85.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 5.